Y-mAbs Therapeutics (NASDAQ:YMAB) Lowered to Sell at ValuEngine

Y-mAbs Therapeutics (NASDAQ:YMAB) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Thursday, ValuEngine reports.

A number of other research firms also recently weighed in on YMAB. HC Wainwright set a $40.00 price target on Y-mAbs Therapeutics and gave the company a “buy” rating in a research note on Monday, August 26th. Wedbush assumed coverage on Y-mAbs Therapeutics in a research note on Tuesday, September 3rd. They issued an “outperform” rating and a $38.00 price target for the company. Cowen restated a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Monday, July 1st. Finally, Zacks Investment Research restated a “hold” rating on shares of Y-mAbs Therapeutics in a research note on Saturday, October 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Y-mAbs Therapeutics has an average rating of “Hold” and a consensus target price of $34.67.

NASDAQ:YMAB opened at $26.80 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.04 and a current ratio of 9.04. The company has a market cap of $863.11 million and a PE ratio of -17.87. Y-mAbs Therapeutics has a 52-week low of $15.17 and a 52-week high of $32.27. The stock has a 50-day simple moving average of $27.33 and a 200 day simple moving average of $24.36.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.05). On average, research analysts predict that Y-mAbs Therapeutics will post -2.1 earnings per share for the current fiscal year.

In other Y-mAbs Therapeutics news, Chairman Thomas Gad sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $25.21, for a total value of $100,840.00. Also, Director Johan Wedell-Wedellsborg sold 89,166 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $26.58, for a total value of $2,370,032.28. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 348,010 shares of company stock valued at $9,425,028. Corporate insiders own 38.40% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of YMAB. BlackRock Inc. boosted its stake in shares of Y-mAbs Therapeutics by 212.6% during the 2nd quarter. BlackRock Inc. now owns 1,153,831 shares of the company’s stock worth $26,387,000 after acquiring an additional 784,672 shares during the period. Artal Group S.A. bought a new position in shares of Y-mAbs Therapeutics during the 2nd quarter worth approximately $9,148,000. Cormorant Asset Management LP lifted its holdings in Y-mAbs Therapeutics by 39.8% during the 2nd quarter. Cormorant Asset Management LP now owns 1,000,000 shares of the company’s stock worth $22,870,000 after purchasing an additional 284,518 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Y-mAbs Therapeutics by 72.0% during the 2nd quarter. Vanguard Group Inc. now owns 489,582 shares of the company’s stock worth $11,196,000 after purchasing an additional 205,021 shares during the last quarter. Finally, AXA acquired a new stake in Y-mAbs Therapeutics during the 2nd quarter worth approximately $3,560,000. Institutional investors own 31.69% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Recommended Story: How can investors find ex-dividend dates?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.